A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 25
- 主要终点
- Best Overall Responses (BOR) Summary Table as Per Central Review by Group - Phase II
研究概览
简要总结
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6 inhibitor
详细描述
This trial had two phases. The purpose of Phase I dose escalation and dose de-escalation was to determine the maximum tolerated doses (MTDs) and/or identify the recommended Phase II dose (RP2D) of the combination treatment of ribociclib+ everolimus + exemestane. The dosing was continuous in adult men and postmenopausal women with HR+ HER2-negative advanced breast cancer which was resistant to the non-steroidal aromatase inhibitors, fulvestrant or tamoxifen.
The purpose of the phase II portion of this trial was to evaluate the anti-tumor activity of exemestane, everolimus and ribociclib combination therapy following progression on a CDK 4/6 inhibitor.
The planned duration of the study was 30 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women
- •Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer
- •Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.
- •ECOG Performance Status 0 - 1
- •Disease refractory to either, AI, tamoxifen or fulvestrant
- •Previously treated on any CDK 4/6 inhibitor.
- •Patient has adequate bone marrow and organ function.
排除标准
- •Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment.
- •Patient has received more than one line of chemotherapy for advanced disease.
- •Previous treatment with mTOR inhibitors, or exemestane for advanced disease.
- •Progressed on more than one CDK 4/6 inhibitor
- •Patient with CNS involvement unless they are at least 4 weeks from prior therapy completion.
- •Clinically significant, uncontrolled heart disease and/or recent cardiac events.
研究组 & 干预措施
Cohort A
Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
干预措施: Ribociclib (Drug)
Cohort A
Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
干预措施: Everolimus (Drug)
Cohort A
Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
干预措施: Exemestane (Drug)
Cohort B
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Ribociclib (Drug)
Cohort B
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Everolimus (Drug)
Cohort B
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Exemestane (Drug)
Cohort C
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Ribociclib (Drug)
Cohort C
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Everolimus (Drug)
Cohort C
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Exemestane (Drug)
Group 1
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Ribociclib (Drug)
Group 1
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Everolimus (Drug)
Group 1
Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Exemestane (Drug)
Group 2
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Ribociclib (Drug)
Group 2
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Everolimus (Drug)
Group 2
Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
干预措施: Exemestane (Drug)
结局指标
主要结局
Best Overall Responses (BOR) Summary Table as Per Central Review by Group - Phase II
时间窗: Baseline up to 24 weeks and at 24 weeks
Complete response (CR) or partial response (PR), or stable disease (SD) at 24 weeks as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Non-CR Non-PD (NCRNPD) at Week 24.
Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I
时间窗: Baseline up to 28 days
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a reasonably possible relationship to the study medication(s) and is unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) and meets any of the criteria defined in the protocol. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading.
Clinical Benefit Rate as Per Central Review by Group- Phase II
时间窗: From baseline up to 24 weeks
Clinical Benefit Rate (CBR) is defined as the percentage of participants with a complete response (CR) or partial response (PR) or with stable disease (SD) as per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 or Non-Complete Response or Non-Progressive Disease (NCRNPD) during first 24 weeks of first dose. CR=disappearance of all non-nodal target lesions, PR=at least a 30% decrease in the sum of diameter of all target lesions, SD=neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD), PD=at least a 20% increase in the sum of diameter of all target lesions. The hypothesis was to be rejected if the lower limit of the 95% Confidence Interval for Clinical Benefit Rate (CBR) was greater than 10%.
次要结局
- Clinical Benefit Rate as Per Central Review by Dose Cohort - Phase I(Baseline up to 24 weeks and at week 24)
- Summary of Progression-free Survival (PFS) (Months), as Per Central Review by Group - Phase II(Baseline up to approximately 32 months)
- Overall Survival (OS) by Group - Phase II(Baseline up to approximately 32 months)
- Duration of Overall Response (DOR) by Group - Phase II(Baseline up to approximately 16 months)
- Time to Definitive Deterioration of ECOG Performance Status in One Category of the Score by Group - Phase II(Baseline up to approximately 8 months)
- Everolimus Pharmacokinetic Plasma Concentrations - Phase II(Cycle 1,2: Day 1 and 15 - pre-dose, 2 and 4 hour post dose, Cycle 3 , Day 1 - pre-dose)
- Everolimus Pharmacokinetic Plasma Concentrations by Cohort - Phase I(Cycle 1,2: Day 1 and 15 - pre-dose, 2 and 4 hour post dose, Cycle 3 , Day 1 - pre-dose)
- Best Overall Responses (BOR) Summary Table as Per Central Review by Cohort - Phase I(From baseline up to 24 weeks)